Definium

Definium Therapeutics Highlights DT120 ODT Progress & Strategy at Investor Day

Definium Therapeutics Showcases DT120 ODT (Lysergide Tartrate) Progress and Commercial Plans at Investor & Analyst Day Definium Therapeutics, a late-stage clinical biopharmaceutical company, recently provided a comprehensive update on the progress of its lead investigational therapy, DT120 ODT (lysergide tartrate),…

Read MoreDefinium Therapeutics Highlights DT120 ODT Progress & Strategy at Investor Day
Federal

Federal Fast-Tracking Boosts Psychedelic Therapies as Segal Trials Prepares for Next Clinical Phase

Federal Push Accelerates Psychedelic Therapies as Clinical Infrastructure Races to Keep Up The landscape of mental health treatment development is undergoing a significant transformation as recent federal action signals a stronger commitment to accelerating psychedelic therapies through the regulatory pipeline.…

Read MoreFederal Fast-Tracking Boosts Psychedelic Therapies as Segal Trials Prepares for Next Clinical Phase
Kallyope

Kallyope Presents Phase 2b Results of Elismetrep for Migraine at AAN Annual Meeting

Kallyope Reports Promising Phase 2b Results for Elismetrep, Introducing a Novel Mechanism for Acute Migraine Treatment Kallyope, a late-stage biotechnology company dedicated to developing innovative therapies for neurological and metabolic disorders, has announced encouraging results from its Phase 2b clinical…

Read MoreKallyope Presents Phase 2b Results of Elismetrep for Migraine at AAN Annual Meeting
Ten

Ten IVI RMA North America Clinics Named to Newsweek’s 2026 Best Fertility Clinics List

Ten IVI RMA North America Clinics Ranked Among Newsweek’s 2026 America’s Best Fertility Clinics IVI RMA North America, a leading provider of fertility care and assisted reproductive technologies, has announced that ten clinics within its expansive national network have been…

Read MoreTen IVI RMA North America Clinics Named to Newsweek’s 2026 Best Fertility Clinics List
Avenzo

Avenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting

Avenzo Therapeutics to Present New Phase 1 Data on AVZO-021 (CDK2 Inhibitor) at the 2026 American Society of Clinical Oncology Annual Meeting Avenzo Therapeutics has announced a significant milestone in its ongoing efforts to develop innovative cancer therapies, revealing that…

Read MoreAvenzo Therapeutics to Share Phase 1 AVZO-021 (CDK2 Inhibitor) Data at the 2026 American Society of Clinical Oncology Annual Meeting
Synthekine

Synthekine Reports Strong STK-012 Activity in First-Line NSCLC at AACR 2026

Synthekine Reports Updated Clinical and Translational Findings for STK-012 in First-Line Non-Squamous NSCLC at AACR 2026 Synthekine, a clinical-stage biotechnology company focused on precision cytokine therapeutics, has released updated clinical and translational data for its investigational therapy STK-012. The results…

Read MoreSynthekine Reports Strong STK-012 Activity in First-Line NSCLC at AACR 2026